Recursion Pharmaceuticals (RXRX) Treasury Shares (2021 - 2026)

Recursion Pharmaceuticals has reported Treasury Shares for 6 years, with the latest figure at $28.6 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 9.14% year-over-year to $28.6 million; the trailing twelve-month figure through Mar 2026 stood at $28.6 million (up 9.14% YoY), and the FY2025 full-year result was $27.5 million, up 0.68% from the prior year.
• Treasury Shares for Q1 2026 stood at $28.6 million, up from $27.5 million in the prior quarter.
• The five-year high for Treasury Shares was $30.6 million in Q3 2025, with the low at $1.4 million in Q1 2022.
• Historically, Treasury Shares has averaged $17.5 million across 5 years, with a median of $18.1 million in 2024.
• Annual changes were most pronounced in 2022 — Treasury Shares jumped 9055.72% — and 2025, when it grew 0.68%.
• Recursion Pharmaceuticals' Treasury Shares stood at $6.9 million in 2022, then soared by 120.81% to $15.2 million in 2023, then surged by 79.35% to $27.3 million in 2024, then grew by 0.68% to $27.5 million in 2025, then climbed by 3.91% to $28.6 million in 2026.
• The last three Treasury Shares figures came in at $28.6 million (Q1 2026), $27.5 million (Q4 2025), and $30.6 million (Q3 2025), per Business Quant data.